Covalon TechnologiesCVALF -1.79%83 Debt-to-EBITDA is 0.38 as of Mar. 2026, which is 3700% above its 10-year median of 0.01. GuruFocus rates CVALF with a GF Score™ of 83/100 and a GF Value™ of $1.53 (Fairly Valued). The stock has 2 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Covalon Technologies ranks better than 61.75% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Covalon Technologies's Debt-to-EBITDA or its related term are showing as below:
CVALF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.15 Med: 0.01 Max: 1.68
Current: 0.85
During the past 13 years, the highest Debt-to-EBITDA Ratio of Covalon Technologies was 1.68. The lowest was -3.15. And the median was 0.01.
CVALF's Debt-to-EBITDA is ranked better than 61.75% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs CVALF: 0.85
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Covalon Technologies Debt-to-EBITDA Related Terms
Covalon Technologies Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Covalon Technologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CVALF vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Covalon Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Covalon Technologies (CVALF) has a Debt-to-EBITDA of 0.38 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Covalon Technologies. This is 3700% above median its historical median of 0.01. According to the industry distribution chart, Covalon Technologies ranks #179 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 38.2%.
Is Covalon Technologies' Debt-to-EBITDA too high?
Covalon Technologies' current Debt-to-EBITDA of 0.38 is 3700% above median its 10-year median of 0.01. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.56. Covalon Technologies' value of 0.38 is 75.6% below this industry median. Based on the distribution chart, Covalon Technologies ranks #179 out of 468 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Covalon Technologies has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #179 out of 468 companies for Debt-to-EBITDA. This puts Covalon Technologies in the upper half of its industry. The industry median Debt-to-EBITDA is 1.56. Covalon Technologies' value of 0.38 is 75.6% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 1.56, Covalon Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current Debt-to-EBITDA of 0.38 is 75.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Covalon Technologies. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current Debt-to-EBITDA is 0.38, which is 3700% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.53, compared to a current price of $1.51 — trading 1.3% below its estimated fair value. The current Debt-to-EBITDA is 0.38, which is 3700% above median its 10-year median of 0.01 and 75.6% below the Medical Devices & Instruments industry median of 1.56. Covalon Technologies' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Debt-to-EBITDA is 0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (CVALF) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be undervalued.
The current stock price of $1.51 is trading 1.3% below its estimated GF Value™ of $1.53.
GuruFocus considers Covalon Technologies to be Fairly Valued.
Key valuation signals for CVALF:
Debt-to-EBITDA: 0.38 (3700% above median its 10-year median of 0.01)
GF Value™: $1.53 vs. price of $1.51 (1.3% below fair value)
Industry Position: 75.6% below the Medical Devices & Instruments median (#179 of 468)
No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
83GF Score
Get the complete analysis for CVALF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVALF has been successfully added to your 
